MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 134 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $1,623,000 | -23.4% | 20,338 | -6.5% | 0.02% | -15.8% |
Q2 2021 | $2,118,000 | -35.3% | 21,744 | -22.3% | 0.02% | -40.6% |
Q1 2021 | $3,273,000 | +5.5% | 27,979 | +0.3% | 0.03% | -8.6% |
Q4 2020 | $3,102,000 | +32.7% | 27,904 | +41.8% | 0.04% | +2.9% |
Q3 2020 | $2,337,000 | -2.0% | 19,682 | -6.5% | 0.03% | +6.2% |
Q2 2020 | $2,384,000 | +27.3% | 21,047 | -25.0% | 0.03% | +10.3% |
Q1 2020 | $1,873,000 | -33.7% | 28,053 | -9.6% | 0.03% | +31.8% |
Q4 2019 | $2,826,000 | +6.6% | 31,020 | +0.9% | 0.02% | +4.8% |
Q3 2019 | $2,652,000 | -21.6% | 30,757 | -4.7% | 0.02% | -16.0% |
Q2 2019 | $3,383,000 | -27.4% | 32,273 | -13.2% | 0.02% | -24.2% |
Q1 2019 | $4,657,000 | +16.1% | 37,180 | +4.5% | 0.03% | +6.5% |
Q4 2018 | $4,010,000 | -31.1% | 35,572 | +30.8% | 0.03% | -18.4% |
Q3 2018 | $5,823,000 | +1.2% | 27,194 | +32.1% | 0.04% | 0.0% |
Q2 2018 | $5,756,000 | +162.5% | 20,579 | +9.6% | 0.04% | +123.5% |
Q1 2018 | $2,193,000 | +72.5% | 18,779 | +35.6% | 0.02% | +88.9% |
Q4 2017 | $1,271,000 | – | 13,847 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |